1626 related articles for article (PubMed ID: 12543786)
21. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
Palli D; Falchetti M; Masala G; Lupi R; Sera F; Saieva C; D'Amico C; Ceroti M; Rizzolo P; Caligo MA; Zanna I; Ottini L
BMC Cancer; 2007 Sep; 7():170. PubMed ID: 17767707
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
Stuppia L; Di Fulvio P; Aceto G; Pintor S; Veschi S; Gatta V; Colosimo A; Cianchetti E; Cama A; Mariani-Costantini R; Battista P; Palka G
Hum Mutat; 2003 Aug; 22(2):178-9. PubMed ID: 12872265
[TBL] [Abstract][Full Text] [Related]
23. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
24. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
Haraldsson K; Loman N; Zhang QX; Johannsson O; Olsson H; Borg A
Cancer Res; 1998 Apr; 58(7):1367-71. PubMed ID: 9537231
[TBL] [Abstract][Full Text] [Related]
25. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
26. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
27. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP
Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202
[TBL] [Abstract][Full Text] [Related]
28. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
29. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
30. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
Hamann U; Liu X; Bungardt N; Ulmer HU; Bastert G; Sinn HP
Eur J Hum Genet; 2003 Jun; 11(6):464-7. PubMed ID: 12774040
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
[TBL] [Abstract][Full Text] [Related]
32. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
[TBL] [Abstract][Full Text] [Related]
33. BRCA2 germline mutations in male breast cancer patients in the Polish population.
Kwiatkowska E; Teresiak M; Lamperska KM; Karczewska A; Breborowicz D; Stawicka M; Godlewski D; Krzyzosiak WJ; Mackiewicz A
Hum Mutat; 2001; 17(1):73. PubMed ID: 11139248
[TBL] [Abstract][Full Text] [Related]
34. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
35. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
36. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
37. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM
Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835
[TBL] [Abstract][Full Text] [Related]
38. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.
Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Scarpi E; Falcini F; Strada M; Morini N; Naldoni C; Amadori D; Calistri D
Breast Cancer Res Treat; 2008 Nov; 112(2):343-9. PubMed ID: 18092194
[TBL] [Abstract][Full Text] [Related]
39. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Papi L; Putignano AL; Congregati C; Zanna I; Sera F; Morrone D; Falchetti M; Turco MR; Ottini L; Palli D; Genuardi M
Breast Cancer Res Treat; 2009 Oct; 117(3):497-504. PubMed ID: 18821011
[TBL] [Abstract][Full Text] [Related]
40. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
